美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

PagerDuty, Inc.

7.82

-0.2200-2.74%

成交量：282.74萬

成交額：2,225.27萬

市值：7.18億

市盈率：4.80

高：7.99

開：7.92

低：7.78

收：8.04

52周最高：19.75

52周最低：7.72

股本：9,177.68萬

流通股本：8,727.34萬

量比：0.59

換手率：3.24%

股息：- -

股息率：- -

每股收益(TTM):1.63

每股收益(LYR):-0.5920

淨資產收益率：66.13%

總資產收益率：-0.59%

市淨率：2.24

市盈率(LYR):-13.21

資料載入中...

總覽公司新聞資訊公告

復宏漢霖PD-1新藥「出海」日本最早將於2028年產生銷售提成

復宏漢霖攜手衞材就抗PD-1單抗漢斯狀達成日本市場合作

南方财经网

釋放pipeline in a drug潛力 NLRP3能否催生下一個「藥王」?

智通财经网

阿斯利康(AZN.US)宣佈PD-L1單抗在華獲批新適應症針對子宮內膜癌

港股異動 | 維立志博-B(09887)升逾4% PD-L1/4-1BB雙抗獲FDA快速通道資格

維立志博-B(09887)：維利信™(PD-L1/4-1BB雙特異性抗體奧帕替蘇米單抗，LBL-024)獲美國FDA授予快速通道資格認定

港股異動 | 復宏漢霖(02696)再升逾8% 廣譜抗腫瘤PD-L1 ADC HLX43末線食管鱗癌II期數據首次發布

PD-1/VEGF雙抗交易熱潮迴歸？榮昌生物簽下56億美元授權

港股異動 | 復宏漢霖(02696)盤中升逾5% 公司首次公布PD-L1 ADC食管鱗狀細胞癌Ⅱ期臨牀數據

維亞臻生物VSA012注射液啓動II期臨牀適應症為活動性狼瘡腎炎等疾病

天士力：PD-L1/VEGF雙抗的實體瘤適應症IIa期、直腸癌適應症IIb期臨牀試驗正在入組中

科倫博泰生物-B(06990)核心產品TROP2 ADC蘆康沙妥珠單抗(SAC-TMT)聯合免疫療法帕博利珠單抗一線治療PD-L1陽性局部晚期或轉移性非小細胞肺癌獲NMPA突破性療法認定

達伯舒新適應症醫保落地系晚期pMMR子宮內膜癌唯一醫保抗PD-(L)1藥物

中国网财经

【新股IPO】國元國際：瀚思艾泰-B(03378)CD47/PD-1雙特異性抗體具備獨特性建議謹慎申購

康辰藥業(603590.SH)：KC1036聯合PD-1抗體和含鉑化療一線治療晚期復發或轉移性食管鱗癌Ⅱ期臨牀研究完成首例受試者入組

產業新聞 | FDA授予百時美施貴寶PD-1療法組合優先審評資格；創新帕金森病免疫療法積極試驗結果公布

港股異動 | 榮昌生物(09995)盤中升逾7% 公布PD-1/VEGF雙抗非小細胞肺癌臨牀數據

和譽-B(02256)：和譽醫藥於ESMO Asia 2025公布口服PD-L1抑制劑ABSK043聯合 EGFR抑制劑伏美替尼治療NSCLC的II期臨牀初步結果

ADC藥物與PD-1/VEGF雙抗聯用再添案例科倫博泰與Crescent達成雙向授權協議

每日经济新闻

ADC與PD-1紅海之外，寶濟藥業如何找到生物醫藥的「第二增長曲線」？

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":7.82,"timestamp":1770670800000,"preClose":8.04,"halted":0,"volume":2827417,"delay":0,"changeRate":-0.02736318407960185,"floatShares":87273400,"shares":91776804,"eps":1.62968,"marketStatus":"盤前交易","change":-0.22,"latestTime":"02-10 04:09:25 EST","open":7.92,"high":7.99,"low":7.775,"amount":22252658.467971202,"amplitude":0.026741,"askPrice":8.6,"askSize":581,"bidPrice":7.77,"bidSize":12,"shortable":3,"etf":0,"ttmEps":1.62968,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1770733800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":7.82,"postHourTrading":{"tag":"盘后","latestPrice":7.85,"preClose":7.82,"latestTime":"19:57 EST","volume":84026,"amount":657132.7778,"timestamp":1770685036439,"change":0.03,"changeRate":0.003836,"amplitude":0.011509},"volumeRatio":0.592988,"impliedVol":0.7932,"impliedVolPercentile":0.976},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","floatShares":87273400,"roa":"-0.59%","roe":"66.13%","lyrEps":-0.591956,"volumeRatio":0.592988,"shares":91776804,"dividePrice":0,"high":7.99,"amplitude":0.026741,"preClose":8.04,"low":7.775,"week52Low":7.715,"pbRate":"2.24","psRate":"1.47","week52High":19.75,"institutionHeld":0,"latestPrice":7.82,"committee":-0.959528,"eps":1.62968,"divideRate":0,"volume":2827417,"delay":0,"ttmEps":1.62968,"open":7.92,"prevYearClose":13.11,"prevWeekClose":8.04,"prevMonthClose":10.6,"prevQuarterClose":13.11,"fiveDayClose":10.38,"twentyDayClose":12.34,"sixtyDayClose":16.11},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-25","symbol":"PD","fiscalQuarterEnding":"2025/10","expectedEps":0.02,"name":null,"time":"盤後","type":"earning","dateTimestamp":1764046800000,"reportTimeType":"post","actualEps":0.15},{"date":"2025-09-03","symbol":"PD","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/07","expectedEps":-0.02,"defaultRemindTime":1756929600000,"name":null,"time":"盤後","dateTimestamp":1756872000000,"actualEps":null},{"market":"US","date":"2025-05-29","symbol":"PD","fiscalQuarterEnding":"2025/04","expectedEps":-0.06,"name":null,"time":"盤後","type":"earning","dateTimestamp":1748491200000,"reportTimeType":"post","actualEps":0},{"market":"US","date":"2025-03-13","symbol":"PD","fiscalQuarterEnding":"2025/01","expectedEps":-0.12,"name":null,"time":"盤後","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2024-11-26","symbol":"PD","fiscalQuarterEnding":"2024/10","expectedEps":-0.11,"name":null,"time":"盤後","type":"earning","dateTimestamp":1732597200000,"reportTimeType":"post","actualEps":-0.03}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.3333,"hold":0.4444,"sell":0.1111,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.4444,"analysts":9,"updateTime":1767848400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PD","date":"2026-02-06","current":4.798488,"percent":0.960232,"low":-115.332138,"twenty":-39.429144,"median":-23.74822,"eighty":-19.674843,"high":9.29824,"avg":-30.283775,"sd":21.43158,"marketCap":722963925},"quantilePoints":[{"date":"2021-02-12","current":-81.051795,"twenty":-68.875403,"median":-45.308378,"eighty":-38.533013,"marketCap":4635757427},{"date":"2021-02-19","current":-74.533844,"twenty":-69.256452,"median":-45.492434,"eighty":-38.599807,"marketCap":4262963219},{"date":"2021-02-26","current":-64.090797,"twenty":-69.256452,"median":-45.616009,"eighty":-38.656949,"marketCap":3665673158},{"date":"2021-03-05","current":-53.862628,"twenty":-69.159583,"median":-45.671397,"eighty":-38.66724,"marketCap":3080673016},{"date":"2021-03-12","current":-60.509506,"twenty":-69.072496,"median":-45.726784,"eighty":-38.673459,"marketCap":3460841176},{"date":"2021-03-19","current":-49.639711,"twenty":-68.918379,"median":-45.797998,"eighty":-38.687063,"marketCap":3420324980},{"date":"2021-03-26","current":-46.372989,"twenty":-68.782324,"median":-45.852876,"eighty":-38.706425,"marketCap":3195238028},{"date":"2021-04-01","current":-49.627656,"twenty":-68.703922,"median":-45.852876,"eighty":-38.74149,"marketCap":3419494401},{"date":"2021-04-09","current":-50.688437,"twenty":-68.634603,"median":-45.95625,"eighty":-38.792193,"marketCap":3492585367},{"date":"2021-04-16","current":-50.965686,"twenty":-68.620415,"median":-46.098464,"eighty":-38.810779,"marketCap":3511688688},{"date":"2021-04-23","current":-50.965686,"twenty":-68.551655,"median":-46.177802,"eighty":-38.849388,"marketCap":3511688688},{"date":"2021-04-30","current":-51.182664,"twenty":-68.073194,"median":-46.296231,"eighty":-38.932876,"marketCap":3526639113},{"date":"2021-05-07","current":-45.52431,"twenty":-67.425697,"median":-46.35136,"eighty":-39.005886,"marketCap":3136761501},{"date":"2021-05-14","current":-42.286432,"twenty":-67.150653,"median":-46.187891,"eighty":-39.046881,"marketCap":2913662055},{"date":"2021-05-21","current":-44.081211,"twenty":-66.824039,"median":-46.121291,"eighty":-39.054259,"marketCap":3037327665},{"date":"2021-05-28","current":-49.295769,"twenty":-66.574781,"median":-46.172553,"eighty":-39.081958,"marketCap":3396626399},{"date":"2021-06-04","current":-36.968776,"twenty":-66.216652,"median":-46.172553,"eighty":-39.072116,"marketCap":2957576028},{"date":"2021-06-11","current":-42.279901,"twenty":-66.096321,"median":-46.075636,"eighty":-39.072116,"marketCap":3382476656},{"date":"2021-06-18","current":-45.709132,"twenty":-65.976077,"median":-45.923735,"eighty":-39.125091,"marketCap":3656821944},{"date":"2021-06-25","current":-47.162372,"twenty":-65.815901,"median":-46.067026,"eighty":-39.183405,"marketCap":3773084124},{"date":"2021-07-02","current":-44.130431,"twenty":-65.216755,"median":-46.011638,"eighty":-39.205083,"marketCap":3530522741},{"date":"2021-07-09","current":-45.834591,"twenty":-65.021933,"median":-45.883552,"eighty":-39.229781,"marketCap":3666858967},{"date":"2021-07-16","current":-40.199362,"twenty":-64.900098,"median":-45.829869,"eighty":-39.313533,"marketCap":3216029363},{"date":"2021-07-23","current":-43.325398,"twenty":-64.76408,"median":-45.766347,"eighty":-39.330284,"marketCap":3466118512},{"date":"2021-07-30","current":-42.436726,"twenty":-64.636745,"median":-45.712576,"eighty":-39.369202,"marketCap":3395022935},{"date":"2021-08-06","current":-44.33953,"twenty":-64.491902,"median":-45.685037,"eighty":-39.631794,"marketCap":3547251112},{"date":"2021-08-13","current":-42.269446,"twenty":-64.377301,"median":-45.655572,"eighty":-39.648544,"marketCap":3381640238},{"date":"2021-08-20","current":-40.387552,"twenty":-64.32,"median":-45.516041,"eighty":-39.732297,"marketCap":3231084897},{"date":"2021-08-27","current":-43.743597,"twenty":-64.248374,"median":-45.492434,"eighty":-39.784241,"marketCap":3499575255},{"date":"2021-09-03","current":-42.390054,"twenty":-64.090797,"median":-45.440934,"eighty":-39.784241,"marketCap":4025995391},{"date":"2021-09-10","current":-39.410762,"twenty":-63.838675,"median":-45.357157,"eighty":-39.773852,"marketCap":3743037083},{"date":"2021-09-17","current":-42.488469,"twenty":-63.43184,"median":-45.291593,"eighty":-39.773852,"marketCap":4035342362},{"date":"2021-09-24","current":-41.531159,"twenty":-63.322968,"median":-45.131991,"eighty":-39.806871,"marketCap":3944421825},{"date":"2021-10-01","current":-37.845067,"twenty":-63.294318,"median":-44.969953,"eighty":-39.673042,"marketCap":3594335269},{"date":"2021-10-08","current":-35.304169,"twenty":-63.234694,"median":-44.895964,"eighty":-39.361418,"marketCap":3353013468},{"date":"2021-10-15","current":-36.968279,"twenty":-62.977151,"median":-44.757709,"eighty":-39.195032,"marketCap":3511062253},{"date":"2021-10-22","current":-37.567716,"twenty":-62.673,"median":-44.689179,"eighty":-39.048237,"marketCap":3567993805},{"date":"2021-10-29","current":-37.352992,"twenty":-62.144822,"median":-44.662724,"eighty":-38.884343,"marketCap":3547600413},{"date":"2021-11-05","current":-38.927633,"twenty":-61.970673,"median":-44.622066,"eighty":-38.780249,"marketCap":3697151952},{"date":"2021-11-12","current":-37.684024,"twenty":-61.914834,"median":-44.517265,"eighty":-38.690435,"marketCap":3579040225},{"date":"2021-11-19","current":-34.892615,"twenty":-61.891288,"median":-44.350719,"eighty":-38.663132,"marketCap":3313926135},{"date":"2021-11-26","current":-33.094304,"twenty":-61.87812,"median":-44.340807,"eighty":-38.647574,"marketCap":3143131480},{"date":"2021-12-03","current":-27.717262,"twenty":-61.851785,"median":-44.310434,"eighty":-38.490518,"marketCap":2632446965},{"date":"2021-12-10","current":-29.437491,"twenty":-61.634212,"median":-44.193031,"eighty":-38.342002,"marketCap":2964590848},{"date":"2021-12-17","current":-29.446029,"twenty":-61.446371,"median":-44.130431,"eighty":-38.122419,"marketCap":2965450648},{"date":"2021-12-23","current":-30.863263,"twenty":-61.141525,"median":-44.120926,"eighty":-37.910083,"marketCap":3108177469},{"date":"2021-12-31","current":-29.668005,"twenty":-60.679678,"median":-44.096614,"eighty":-37.767931,"marketCap":2987805451},{"date":"2022-01-07","current":-27.243339,"twenty":-60.561077,"median":-44.020576,"eighty":-37.685906,"marketCap":2743622214},{"date":"2022-01-14","current":-26.466422,"twenty":-60.402519,"median":-43.931787,"eighty":-37.609143,"marketCap":2665380403},{"date":"2022-01-21","current":-25.715117,"twenty":-60.229637,"median":-43.82863,"eighty":-37.535067,"marketCap":2589717991},{"date":"2022-01-28","current":-27.448241,"twenty":-60.179262,"median":-43.748751,"eighty":-37.457573,"marketCap":2764257417},{"date":"2022-02-04","current":-27.106738,"twenty":-60.125395,"median":-43.643849,"eighty":-37.310047,"marketCap":2729865412},{"date":"2022-02-11","current":-28.728874,"twenty":-59.884929,"median":-43.550718,"eighty":-37.143446,"marketCap":2893227437},{"date":"2022-02-18","current":-27.106738,"twenty":-59.724487,"median":-43.492185,"eighty":-36.968378,"marketCap":2729865412},{"date":"2022-02-25","current":-28.071482,"twenty":-59.678646,"median":-43.437917,"eighty":-36.905651,"marketCap":2827022827},{"date":"2022-03-04","current":-25.322389,"twenty":-59.583656,"median":-43.360924,"eighty":-36.834452,"marketCap":2550167185},{"date":"2022-03-11","current":-22.70136,"twenty":-59.306192,"median":-43.319423,"eighty":-36.766338,"marketCap":2286208545},{"date":"2022-03-18","current":-28.291592,"twenty":-59.172166,"median":-43.295217,"eighty":-36.444632,"marketCap":3040073042},{"date":"2022-03-25","current":-28.785804,"twenty":-59.048339,"median":-43.241759,"eighty":-36.064649,"marketCap":3093178556},{"date":"2022-04-01","current":-27.724464,"twenty":-59.048339,"median":-43.1764,"eighty":-35.678665,"marketCap":2979132288},{"date":"2022-04-08","current":-25.415442,"twenty":-58.958192,"median":-43.086807,"eighty":-35.293402,"marketCap":2731016361},{"date":"2022-04-14","current":-26.428171,"twenty":-58.866018,"median":-43.039133,"eighty":-34.945236,"marketCap":2839839136},{"date":"2022-04-22","current":-23.843687,"twenty":-58.778063,"median":-42.940117,"eighty":-34.48789,"marketCap":2562123414},{"date":"2022-04-29","current":-23.14693,"twenty":-58.704534,"median":-42.888728,"eighty":-33.407653,"marketCap":2487253345},{"date":"2022-05-06","current":-21.039181,"twenty":-58.614907,"median":-42.82356,"eighty":-33.196501,"marketCap":2260765197},{"date":"2022-05-13","current":-21.537198,"twenty":-58.533862,"median":-42.744231,"eighty":-33.138326,"marketCap":2314279623},{"date":"2022-05-20","current":-19.528801,"twenty":-58.506847,"median":-42.67719,"eighty":-32.784627,"marketCap":2098467346},{"date":"2022-05-27","current":-21.055509,"twenty":-58.47232,"median":-42.506172,"eighty":-32.56425,"marketCap":2262519768},{"date":"2022-06-03","current":-19.41561,"twenty":-58.365647,"median":-42.492303,"eighty":-32.253988,"marketCap":2285547362},{"date":"2022-06-10","current":-18.661968,"twenty":-58.119439,"median":-42.449993,"eighty":-31.627913,"marketCap":2196830881},{"date":"2022-06-17","current":-17.871017,"twenty":-57.794408,"median":-42.412967,"eighty":-30.853018,"marketCap":2103722495},{"date":"2022-06-24","current":-21.251213,"twenty":-57.545961,"median":-42.37641,"eighty":-30.527663,"marketCap":2501629088},{"date":"2022-07-01","current":-18.975364,"twenty":-57.27835,"median":-42.328632,"eighty":-30.205871,"marketCap":2233722883},{"date":"2022-07-08","current":-20.758734,"twenty":-57.119373,"median":-42.300639,"eighty":-29.937792,"marketCap":2443655942},{"date":"2022-07-15","current":-19.512613,"twenty":-57.022546,"median":-42.274674,"eighty":-29.686169,"marketCap":2296966315},{"date":"2022-07-22","current":-19.751391,"twenty":-56.538634,"median":-42.258991,"eighty":-29.576542,"marketCap":2325074507},{"date":"2022-07-29","current":-19.348454,"twenty":-55.37095,"median":-42.1379,"eighty":-29.489533,"marketCap":2277641933},{"date":"2022-08-05","current":-21.340755,"twenty":-54.581356,"median":-41.999461,"eighty":-29.249821,"marketCap":2512169660},{"date":"2022-08-12","current":-21.370602,"twenty":-54.282209,"median":-41.907002,"eighty":-28.899625,"marketCap":2515683184},{"date":"2022-08-19","current":-19.214141,"twenty":-54.164004,"median":-41.742363,"eighty":-28.761236,"marketCap":2261831075},{"date":"2022-08-26","current":-19.318607,"twenty":-54.013801,"median":-41.687142,"eighty":-28.490216,"marketCap":2274128409},{"date":"2022-09-02","current":-16.562766,"twenty":-53.825684,"median":-41.612639,"eighty":-28.401837,"marketCap":2096100841},{"date":"2022-09-09","current":-17.753369,"twenty":-53.67791,"median":-41.5952,"eighty":-28.368118,"marketCap":2246777593},{"date":"2022-09-16","current":-16.597991,"twenty":-53.584381,"median":-41.569297,"eighty":-28.257217,"marketCap":2100558733},{"date":"2022-09-23","current":-15.858267,"twenty":-53.533149,"median":-41.530643,"eighty":-28.105632,"marketCap":2006943000},{"date":"2022-09-30","current":-16.252786,"twenty":-53.345477,"median":-41.466004,"eighty":-27.873415,"marketCap":2056871391},{"date":"2022-10-07","current":-16.182337,"twenty":-53.110426,"median":-41.390601,"eighty":-27.717262,"marketCap":2047955607},{"date":"2022-10-14","current":-14.646529,"twenty":-52.79331,"median":-41.34773,"eighty":-27.636067,"marketCap":1853591514},{"date":"2022-10-21","current":-16.485271,"twenty":-52.578578,"median":-41.307589,"eighty":-27.328715,"marketCap":2086293479},{"date":"2022-10-28","current":-17.922449,"twenty":-52.484531,"median":-41.281723,"eighty":-27.012825,"marketCap":2268175475},{"date":"2022-11-04","current":-14.604259,"twenty":-52.445692,"median":-41.223096,"eighty":-26.683037,"marketCap":1848242043},{"date":"2022-11-11","current":-17.35885,"twenty":-52.440537,"median":-41.165581,"eighty":-26.46868,"marketCap":2196849202},{"date":"2022-11-18","current":-15.442613,"twenty":-51.97825,"median":-41.046215,"eighty":-26.415612,"marketCap":1954339874},{"date":"2022-11-25","current":-15.379208,"twenty":-51.971496,"median":-40.952393,"eighty":-26.24103,"marketCap":1946315669},{"date":"2022-12-02","current":-16.042428,"twenty":-51.941247,"median":-40.886211,"eighty":-26.002015,"marketCap":2129728606},{"date":"2022-12-09","current":-16.110204,"twenty":-51.872986,"median":-40.837833,"eighty":-25.713912,"marketCap":2138726192},{"date":"2022-12-16","current":-18.028246,"twenty":-51.7604,"median":-40.772608,"eighty":-25.598799,"marketCap":2393357876},{"date":"2022-12-23","current":-17.994359,"twenty":-51.70784,"median":-40.745253,"eighty":-25.338499,"marketCap":2388859083},{"date":"2022-12-30","current":-18.001136,"twenty":-51.570726,"median":-40.701201,"eighty":-25.184081,"marketCap":2389758841},{"date":"2023-01-06","current":-16.049206,"twenty":-51.363479,"median":-40.623172,"eighty":-24.85486,"marketCap":2130628364},{"date":"2023-01-13","current":-18.78733,"twenty":-51.102161,"median":-40.574619,"eighty":-24.231092,"marketCap":2494130839},{"date":"2023-01-20","current":-18.882216,"twenty":-50.978262,"median":-40.523325,"eighty":-23.99114,"marketCap":2506727459},{"date":"2023-01-27","current":-19.925957,"twenty":-50.965686,"median":-40.469321,"eighty":-23.312385,"marketCap":2645290284},{"date":"2023-02-03","current":-21.220466,"twenty":-50.951221,"median":-40.311267,"eighty":-22.57339,"marketCap":2817144176},{"date":"2023-02-10","current":-19.627745,"twenty":-50.890949,"median":-40.250171,"eighty":-21.596594,"marketCap":2605700905},{"date":"2023-02-17","current":-20.664708,"twenty":-50.876484,"median":-40.190227,"eighty":-21.430411,"marketCap":2743363971},{"date":"2023-02-24","current":-19.485417,"twenty":-50.857197,"median":-40.120759,"eighty":-21.251213,"marketCap":2586805975},{"date":"2023-03-03","current":-20.834146,"twenty":-50.688437,"median":-40.045986,"eighty":-21.055509,"marketCap":2765857936},{"date":"2023-03-10","current":-18.204462,"twenty":-50.646894,"median":-39.953806,"eighty":-20.967665,"marketCap":2416751599},{"date":"2023-03-17","current":-22.814647,"twenty":-50.628165,"median":-39.81605,"eighty":-20.881589,"marketCap":2929925462},{"date":"2023-03-24","current":-22.508745,"twenty":-50.547877,"median":-39.758269,"eighty":-20.937818,"marketCap":2890640524},{"date":"2023-03-31","current":-24.884826,"twenty":-50.538628,"median":-39.648544,"eighty":-20.967665,"marketCap":3195783993},{"date":"2023-04-06","current":-22.608341,"twenty":-50.398102,"median":-39.410762,"eighty":-20.985573,"marketCap":2903430969},{"date":"2023-04-14","current":-23.753697,"twenty":-50.260054,"median":-39.321908,"eighty":-21.029355,"marketCap":3050521084},{"date":"2023-04-21","current":-24.273021,"twenty":-50.211876,"median":-39.198908,"eighty":-21.041663,"marketCap":3117214118},{"date":"2023-04-28","current":-22.053448,"twenty":-50.10983,"median":-39.086878,"eighty":-21.052864,"marketCap":2832169920},{"date":"2023-05-05","current":-20.085339,"twenty":-50.030853,"median":-39.045525,"eighty":-21.029355,"marketCap":2579419472},{"date":"2023-05-12","current":-21.254175,"twenty":-50.011348,"median":-38.97946,"eighty":-20.981096,"marketCap":2729524925},{"date":"2023-05-19","current":-21.074906,"twenty":-49.936988,"median":-38.858126,"eighty":-20.935287,"marketCap":2706502616},{"date":"2023-05-26","current":-18.98821,"twenty":-49.739821,"median":-38.781427,"eighty":-20.865452,"marketCap":2438522942},{"date":"2023-06-02","current":-23.7011,"twenty":-49.634889,"median":-38.748697,"eighty":-20.83367,"marketCap":2555476271},{"date":"2023-06-09","current":-19.16437,"twenty":-49.587066,"median":-38.685442,"eighty":-20.780404,"marketCap":2066321490},{"date":"2023-06-16","current":-19.591955,"twenty":-49.518553,"median":-38.668128,"eighty":-20.758997,"marketCap":2112424156},{"date":"2023-06-23","current":-18.642716,"twenty":-49.490829,"median":-38.652026,"eighty":-20.740419,"marketCap":2010076237},{"date":"2023-06-30","current":-18.830853,"twenty":-49.425691,"median":-38.650282,"eighty":-20.728887,"marketCap":2030361410},{"date":"2023-07-07","current":-18.753888,"twenty":-49.321753,"median":-38.534252,"eighty":-20.640309,"marketCap":2022062930},{"date":"2023-07-14","current":-21.12271,"twenty":-49.135663,"median":-38.486364,"eighty":-20.586625,"marketCap":2277471700},{"date":"2023-07-21","current":-20.626711,"twenty":-49.077653,"median":-38.375503,"eighty":-20.595005,"marketCap":2223992607},{"date":"2023-07-28","current":-21.105606,"twenty":-49.061015,"median":-38.330676,"eighty":-20.595005,"marketCap":2275627593},{"date":"2023-08-04","current":-20.883262,"twenty":-49.007339,"median":-38.158206,"eighty":-20.613914,"marketCap":2251654207},{"date":"2023-08-11","current":-20.549746,"twenty":-48.954208,"median":-37.988814,"eighty":-20.586625,"marketCap":2215694127},{"date":"2023-08-18","current":-20.01954,"twenty":-48.941266,"median":-37.845067,"eighty":-20.541194,"marketCap":2158526822},{"date":"2023-08-25","current":-20.66947,"twenty":-48.894876,"median":-37.770349,"eighty":-20.506987,"marketCap":2228602874},{"date":"2023-09-01","current":-25.511357,"twenty":-48.832826,"median":-37.755599,"eighty":-20.541194,"marketCap":2375209352},{"date":"2023-09-07","current":-24.043412,"twenty":-48.807682,"median":-37.686377,"eighty":-20.560008,"marketCap":2238537799},{"date":"2023-09-14","current":-23.412009,"twenty":-48.750972,"median":-37.671633,"eighty":-20.577111,"marketCap":2179751687},{"date":"2023-09-22","current":-22.590183,"twenty":-48.595885,"median":-37.578261,"eighty":-20.58462,"marketCap":2103236431},{"date":"2023-09-28","current":-22.048981,"twenty":-48.583225,"median":-37.547623,"eighty":-20.587293,"marketCap":2052848336},{"date":"2023-10-05","current":-21.978825,"twenty":-48.576545,"median":-37.531928,"eighty":-20.595005,"marketCap":2046316545},{"date":"2023-10-11","current":-21.497757,"twenty":-48.562801,"median":-37.500901,"eighty":-20.605423,"marketCap":2001527127},{"date":"2023-10-20","current":-20.345196,"twenty":-48.534663,"median":-37.448341,"eighty":-20.589221,"marketCap":1894219146},{"date":"2023-10-27","current":-19.894194,"twenty":-48.514606,"median":-37.410785,"eighty":-20.580532,"marketCap":1852229066},{"date":"2023-11-03","current":-20.485508,"twenty":-48.433814,"median":-37.299311,"eighty":-20.506205,"marketCap":1907282726},{"date":"2023-11-10","current":-20.746087,"twenty":-48.370598,"median":-37.219715,"eighty":-20.506987,"marketCap":1931543661},{"date":"2023-11-17","current":-21.217133,"twenty":-48.32991,"median":-37.120374,"eighty":-20.524091,"marketCap":1975399966},{"date":"2023-11-24","current":-21.858558,"twenty":-48.320008,"median":-37.057747,"eighty":-20.549746,"marketCap":2035119191},{"date":"2023-11-30","current":-22.048981,"twenty":-48.252059,"median":-36.968279,"eighty":-20.57027,"marketCap":2052848336},{"date":"2023-12-07","current":-26.625426,"twenty":-48.121131,"median":-36.925787,"eighty":-20.578821,"marketCap":2015198621},{"date":"2023-12-15","current":-28.276615,"twenty":-48.00719,"median":-36.911135,"eighty":-20.582242,"marketCap":2140172179},{"date":"2024-01-05","current":-26.103359,"twenty":-47.918569,"median":-36.904212,"eighty":-20.585288,"marketCap":1975684923},{"date":"2024-01-12","current":-31.117632,"twenty":-47.865829,"median":-36.842529,"eighty":-20.591149,"marketCap":2355200212},{"date":"2024-01-19","current":-31.627558,"twenty":-47.844972,"median":-36.829603,"eighty":-20.601178,"marketCap":2393794988},{"date":"2024-01-26","current":-29.053645,"twenty":-47.78321,"median":-36.766338,"eighty":-20.619869,"marketCap":2198983265},{"date":"2024-02-02","current":-29.32075,"twenty":-47.731847,"median":-36.504107,"eighty":-20.628421,"marketCap":2219199576},{"date":"2024-02-09","current":-29.393596,"twenty":-47.672575,"median":-36.388531,"eighty":-20.635263,"marketCap":2224713115},{"date":"2024-02-16","current":-29.733547,"twenty":-47.618326,"median":-36.095963,"eighty":-20.635379,"marketCap":2250442965},{"date":"2024-02-23","current":-28.10664,"twenty":-47.602066,"median":-35.89466,"eighty":-20.635842,"marketCap":2127307254},{"date":"2024-03-01","current":-29.332891,"twenty":-47.570415,"median":-35.678665,"eighty":-20.651153,"marketCap":2220118499},{"date":"2024-03-08","current":-29.55143,"twenty":-47.518149,"median":-35.35785,"eighty":-20.660918,"marketCap":2236659117},{"date":"2024-03-15","current":-26.009561,"twenty":-47.49129,"median":-35.24315,"eighty":-20.664708,"marketCap":2126463652},{"date":"2024-03-22","current":-25.786705,"twenty":-47.380514,"median":-34.925503,"eighty":-20.66947,"marketCap":2108243640},{"date":"2024-03-28","current":-24.935846,"twenty":-47.342533,"median":-34.589879,"eighty":-20.66947,"marketCap":2038679948},{"date":"2024-04-05","current":-25.071983,"twenty":-47.312176,"median":-34.414946,"eighty":-20.689994,"marketCap":2049810139},{"date":"2024-04-12","current":-25.888808,"twenty":-47.269427,"median":-33.423363,"eighty":-20.697474,"marketCap":2116591283},{"date":"2024-04-19","current":-23.631195,"twenty":-47.158961,"median":-33.184171,"eighty":-20.697474,"marketCap":1932015619},{"date":"2024-04-26","current":-22.916473,"twenty":-46.951231,"median":-33.003753,"eighty":-20.698257,"marketCap":1873582118},{"date":"2024-05-03","current":-23.897861,"twenty":-46.656905,"median":-32.649248,"eighty":-20.698257,"marketCap":1953817432},{"date":"2024-05-10","current":-23.114516,"twenty":-46.598159,"median":-32.247909,"eighty":-20.698257,"marketCap":1889773514},{"date":"2024-05-17","current":-24.517522,"twenty":-46.43348,"median":-31.759443,"eighty":-20.698257,"marketCap":2004479038},{"date":"2024-05-24","current":-22.904066,"twenty":-46.181838,"median":-31.451512,"eighty":-20.698257,"marketCap":1872567685},{"date":"2024-05-31","current":-20.986625,"twenty":-46.068748,"median":-31.128449,"eighty":-20.698257,"marketCap":1715803469},{"date":"2024-06-07","current":-20.224161,"twenty":-45.830813,"median":-30.643949,"eighty":-20.66395,"marketCap":1892880316},{"date":"2024-06-14","current":-21.429439,"twenty":-45.725202,"median":-30.31849,"eighty":-20.645029,"marketCap":2005688335},{"date":"2024-06-21","current":-21.357939,"twenty":-45.671397,"median":-29.967092,"eighty":-20.641966,"marketCap":1998996334},{"date":"2024-06-28","current":-23.247571,"twenty":-45.51108,"median":-29.932669,"eighty":-20.635726,"marketCap":2175856364},{"date":"2024-07-05","current":-22.542789,"twenty":-45.42729,"median":-29.794252,"eighty":-20.635726,"marketCap":2109892353},{"date":"2024-07-12","current":-21.439653,"twenty":-45.27192,"median":-29.668005,"eighty":-20.635726,"marketCap":2006644335},{"date":"2024-07-15","current":-21.807365,"twenty":-45.165128,"median":-29.6527,"eighty":-20.635726,"marketCap":2041060341},{"date":"2024-08-02","current":-20.438659,"twenty":-44.67116,"median":-29.473821,"eighty":-20.619869,"marketCap":1912956320},{"date":"2024-08-09","current":-18.937169,"twenty":-44.592228,"median":-29.326821,"eighty":-20.554877,"marketCap":1772424296},{"date":"2024-08-16","current":-19.846234,"twenty":-44.342086,"median":-29.065787,"eighty":-20.488395,"marketCap":1857508310},{"date":"2024-08-23","current":-19.366166,"twenty":-44.293477,"median":-28.968658,"eighty":-20.439367,"marketCap":1812576303},{"date":"2024-08-30","current":-20.193518,"twenty":-44.126836,"median":-28.878841,"eighty":-20.396729,"marketCap":1890012316},{"date":"2024-09-06","current":-20.851386,"twenty":-44.070828,"median":-28.815003,"eighty":-20.350301,"marketCap":1731811836},{"date":"2024-09-13","current":-19.495653,"twenty":-43.902513,"median":-28.750118,"eighty":-20.261779,"marketCap":1619211496},{"date":"2024-09-20","current":-20.358392,"twenty":-43.724824,"median":-28.493474,"eighty":-20.244564,"marketCap":1690866258},{"date":"2024-09-27","current":-20.324779,"twenty":-43.52784,"median":-28.425739,"eighty":-20.226358,"marketCap":1688074514},{"date":"2024-10-04","current":-19.753355,"twenty":-43.367535,"median":-28.373476,"eighty":-20.209123,"marketCap":1640614867},{"date":"2024-10-11","current":-20.30237,"twenty":-43.311657,"median":-28.264591,"eighty":-20.195561,"marketCap":1686213351},{"date":"2024-10-18","current":-21.030656,"twenty":-43.248031,"median":-28.136018,"eighty":-20.195561,"marketCap":1746701137},{"date":"2024-10-25","current":-20.078282,"twenty":-43.248031,"median":-28.049113,"eighty":-20.145499,"marketCap":1667601725},{"date":"2024-10-31","current":-20.649706,"twenty":-43.248031,"median":-27.765641,"eighty":-20.132647,"marketCap":1715061372},{"date":"2024-11-08","current":-22.688907,"twenty":-43.252213,"median":-27.636067,"eighty":-20.132233,"marketCap":1884427173},{"date":"2024-11-15","current":-21.960621,"twenty":-43.252213,"median":-27.448241,"eighty":-20.132233,"marketCap":1823939387},{"date":"2024-11-22","current":-22.229527,"twenty":-43.231304,"median":-27.106738,"eighty":-20.132233,"marketCap":1846273338},{"date":"2024-11-29","current":-25.707412,"twenty":-43.145724,"median":-26.876224,"eighty":-20.132233,"marketCap":1914893729},{"date":"2024-12-06","current":-25.40483,"twenty":-43.145724,"median":-26.625426,"eighty":-20.132233,"marketCap":1892354961},{"date":"2024-12-13","current":-24.521289,"twenty":-43.145724,"median":-26.466422,"eighty":-20.132233,"marketCap":1826541758},{"date":"2024-12-20","current":-22.572657,"twenty":-43.145724,"median":-26.327469,"eighty":-20.132233,"marketCap":1681392092},{"date":"2024-12-27","current":-22.173248,"twenty":-43.145724,"median":-26.203648,"eighty":-20.132233,"marketCap":1651640919},{"date":"2025-01-03","current":-21.785943,"twenty":-43.145724,"median":-26.12294,"eighty":-20.132233,"marketCap":1622791296},{"date":"2025-01-10","current":-21.434947,"twenty":-43.151859,"median":-25.994723,"eighty":-20.130744,"marketCap":1596646325},{"date":"2025-01-17","current":-22.584761,"twenty":-43.151859,"median":-25.832017,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-24","current":-22.584761,"twenty":-43.151859,"median":-25.722549,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-31","current":-22.330591,"twenty":-43.151859,"median":-25.688138,"eighty":-20.130744,"marketCap":1663361078},{"date":"2025-02-07","current":-23.032583,"twenty":-43.151859,"median":-25.544418,"eighty":-20.130744,"marketCap":1715651020},{"date":"2025-02-14","current":-23.601438,"twenty":-43.151859,"median":-25.410136,"eighty":-20.130744,"marketCap":1758023904},{"date":"2025-02-21","current":-22.149042,"twenty":-43.151859,"median":-25.353801,"eighty":-20.130744,"marketCap":1649837817},{"date":"2025-02-28","current":-21.229191,"twenty":-43.151859,"median":-25.248903,"eighty":-20.130744,"marketCap":1581319962},{"date":"2025-03-07","current":-20.902402,"twenty":-43.157994,"median":-25.114351,"eighty":-20.129255,"marketCap":1556978093},{"date":"2025-03-14","current":-25.841364,"twenty":-43.157994,"median":-25.015259,"eighty":-20.118618,"marketCap":1407320673},{"date":"2025-03-21","current":-31.526661,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1716941957},{"date":"2025-03-28","current":-31.810986,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1732426315},{"date":"2025-04-04","current":-28.415807,"twenty":-43.157994,"median":-25.140052,"eighty":-20.118618,"marketCap":1547524873},{"date":"2025-04-11","current":-25.672904,"twenty":-43.151859,"median":-25.115856,"eighty":-20.120859,"marketCap":1398146368},{"date":"2025-04-17","current":-25.238054,"twenty":-43.151859,"median":-25.115856,"eighty":-20.120859,"marketCap":1374464410},{"date":"2025-04-25","current":-26.22483,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1428204238},{"date":"2025-05-02","current":-26.007405,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1416363259},{"date":"2025-05-09","current":-26.208105,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1427293394},{"date":"2025-05-16","current":-28.064582,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1528397138},{"date":"2025-05-23","current":-26.826931,"twenty":-43.110374,"median":-25.054079,"eighty":-20.118618,"marketCap":1460994642},{"date":"2025-05-30","current":-40.212905,"twenty":-43.110374,"median":-25.054079,"eighty":-20.118618,"marketCap":1483896395},{"date":"2025-06-06","current":-38.417271,"twenty":-42.89345,"median":-25.054079,"eighty":-20.118618,"marketCap":1417635735},{"date":"2025-06-13","current":-37.443101,"twenty":-42.85482,"median":-25.054079,"eighty":-20.118618,"marketCap":1381687885},{"date":"2025-06-20","current":-35.644634,"twenty":-42.692819,"median":-25.045717,"eighty":-20.116377,"marketCap":1315322623},{"date":"2025-06-27","current":-37.218293,"twenty":-42.4845,"median":-25.045717,"eighty":-20.116377,"marketCap":1373392227},{"date":"2025-07-03","current":-39.940973,"twenty":-42.385562,"median":-25.045717,"eighty":-20.116377,"marketCap":1473861860},{"date":"2025-07-11","current":-39.516335,"twenty":-42.275719,"median":-25.045717,"eighty":-20.116377,"marketCap":1458192284},{"date":"2025-07-18","current":-36.593825,"twenty":-42.275719,"median":-25.045717,"eighty":-20.116377,"marketCap":1350348733},{"date":"2025-07-25","current":-36.743697,"twenty":-42.001222,"median":-25.045717,"eighty":-20.116377,"marketCap":1355879172},{"date":"2025-08-01","current":-40.265697,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1485844477},{"date":"2025-08-08","current":-38.941825,"twenty":-41.552011,"median":-25.045717,"eighty":-20.116377,"marketCap":1436992270},{"date":"2025-08-15","current":-38.667059,"twenty":-41.27534,"median":-25.045717,"eighty":-20.116377,"marketCap":1426853133},{"date":"2025-08-22","current":-39.441399,"twenty":-41.020287,"median":-25.045717,"eighty":-20.116377,"marketCap":1455427065},{"date":"2025-08-29","current":-42.263994,"twenty":-40.940123,"median":-25.045717,"eighty":-20.116377,"marketCap":1559583657},{"date":"2025-09-05","current":-111.301894,"twenty":-40.946258,"median":-25.037354,"eighty":-20.114136,"marketCap":1545092897},{"date":"2025-09-12","current":-111.369065,"twenty":-41.159237,"median":-25.045717,"eighty":-20.116377,"marketCap":1546025361},{"date":"2025-09-19","current":-110.361504,"twenty":-41.502219,"median":-25.045717,"eighty":-20.116377,"marketCap":1532038401},{"date":"2025-09-26","current":-108.816577,"twenty":-41.627318,"median":-25.045717,"eighty":-20.116377,"marketCap":1510591728},{"date":"2025-10-03","current":-110.630187,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1535768257},{"date":"2025-10-10","current":-109.824138,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1524578689},{"date":"2025-10-17","current":-105.659553,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1466765919},{"date":"2025-10-24","current":-107.540334,"twenty":-41.713376,"median":-25.045717,"eighty":-20.116377,"marketCap":1492874912},{"date":"2025-10-31","current":-105.793895,"twenty":-41.746269,"median":-25.045717,"eighty":-20.116377,"marketCap":1468630847},{"date":"2025-11-07","current":-101.562139,"twenty":-41.812397,"median":-25.045717,"eighty":-20.116377,"marketCap":1409885613},{"date":"2025-11-14","current":-104.719163,"twenty":-41.812397,"median":-25.045717,"eighty":-20.116377,"marketCap":1453711422},{"date":"2025-11-21","current":-98.740968,"twenty":-41.812397,"median":-25.045717,"eighty":-20.116377,"marketCap":1370722124},{"date":"2025-11-28","current":6.997444,"twenty":-41.746269,"median":-24.978468,"eighty":-20.091839,"marketCap":1065227860},{"date":"2025-12-05","current":7.219871,"twenty":-41.569584,"median":-24.845699,"eighty":-20.051536,"marketCap":1099088196},{"date":"2025-12-12","current":7.833049,"twenty":-41.149298,"median":-24.524361,"eighty":-20.010479,"marketCap":1192432905},{"date":"2025-12-19","current":7.79698,"twenty":-40.783904,"median":-24.456235,"eighty":-19.933106,"marketCap":1186942040},{"date":"2025-12-26","current":7.839061,"twenty":-40.638471,"median":-24.290539,"eighty":-19.921421,"marketCap":1193348049},{"date":"2026-01-02","current":7.881142,"twenty":-40.445544,"median":-24.213538,"eighty":-19.883804,"marketCap":1199754059},{"date":"2026-01-09","current":7.616633,"twenty":-40.245714,"median":-24.133436,"eighty":-19.850083,"marketCap":1159487714},{"date":"2026-01-16","current":7.105652,"twenty":-40.140803,"median":-24.036721,"eighty":-19.806911,"marketCap":1081700456},{"date":"2026-01-23","current":6.738947,"twenty":-40.000922,"median":-23.900481,"eighty":-19.757821,"marketCap":1025876659},{"date":"2026-01-30","current":6.318139,"twenty":-39.844633,"median":-23.836174,"eighty":-19.718173,"marketCap":961816564},{"date":"2026-02-06","current":4.749124,"twenty":-39.429144,"median":-23.74822,"eighty":-19.674843,"marketCap":722963925}],"updateTime":1770714565237},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609752625","title":"復宏漢霖PD-1新藥「出海」日本 最早將於2028年產生銷售提成","url":"https://stock-news.laohu8.com/highlight/detail?id=2609752625","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609752625?lang=zh_tw&edition=fundamental","pubTime":"2026-02-08 17:39","pubTimestamp":1770543568,"startTime":"0","endTime":"0","summary":"日前，上海复宏汉霖生物技术股份有限公司（以下简称“复宏汉霖”）与卫材株式会社（以下简称“卫材”）共同宣布，双方已就抗PD-1单抗汉斯状（斯鲁利单抗，以下简称“PD-1新药”）在日本达成一项独家商业化及共同独家开发与生产许可协议。汉斯状是复宏汉霖自主研发的一款PD-1新药。根据协议，卫材将获得汉斯状在日本的独家商业化权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602083644840016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","PD","HK0000165453.HKD","LU1169589451.USD","02696","HK0000306701.USD","BK4023","HK0000320223.HKD","LU1169590202.USD","HK0000320264.USD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2609375221","title":"復宏漢霖攜手衞材就抗PD-1單抗漢斯狀達成日本市場合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2609375221","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609375221?lang=zh_tw&edition=fundamental","pubTime":"2026-02-05 18:33","pubTimestamp":1770287601,"startTime":"0","endTime":"0","summary":"南方财经2月5日电，卫材与复宏汉霖今日共同宣布，双方已就抗PD-1单抗H药汉斯状?（斯鲁利单抗，欧洲商品名：Hetronifly?）在日本达成一项独家商业化及共同独家开发与生产许可协议。根据协议，卫材将向复宏汉霖支付7,500万美元的首付款，并在此基础上，支付最高不超过8,001万美元的监管里程碑付款，以及最高不超过2.333亿美元的销售里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642892718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","BK4023","HK0000320223.HKD","HK0000306685.HKD","EWJ","LU1169590202.USD","BK1161","HK0000320264.USD","HK0000306701.USD","PD","02696","BK4588","LU1169589451.USD","BK4585"],"gpt_icon":0},{"id":"2609432256","title":"釋放pipeline in a drug潛力 NLRP3能否催生下一個「藥王」?","url":"https://stock-news.laohu8.com/highlight/detail?id=2609432256","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609432256?lang=zh_tw&edition=fundamental","pubTime":"2026-02-05 16:35","pubTimestamp":1770280559,"startTime":"0","endTime":"0","summary":"近期，英硅智能(03696)宣布提名靶向NLRP3的外周限制性抑制剂ISM5059，该候选药物具有新颖母核，由英硅智能自有Pharma.AI平台驱动设计。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260205/20260205163220_51027.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260205/20260205163220_51027.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4132","BK4135","LU1169590202.USD","PD","AD","BBB","IBD","CNS","LU1169589451.USD","BK4023"],"gpt_icon":0},{"id":"2605290194","title":"阿斯利康(AZN.US)宣佈PD-L1單抗在華獲批新適應症 針對子宮內膜癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2605290194","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605290194?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 14:42","pubTimestamp":1769150545,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月22日，阿斯利康宣布，英飞凡已获中国国家药品监督管理局批准，与卡铂和紫杉醇联合用于错配修复缺陷的原发晚期或复发性子宫内膜癌成人患者的一线治疗，随后以本品单药维持治疗。截至目前该药已在美国获批 10 项适应症，在欧盟获批 11 项适应症，在国内获批 7 项。安全性方面，度伐利尤单抗联合化疗方案的总体安全性和耐受性良好，并且与此前临床试验结果总体一致，没有出现新的安全信号。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2417539215.USD","BK4023","AZN","BK4007","LU0320765992.SGD","LU1169590202.USD","LU2456880835.USD","LU1169589451.USD","LU2462157665.USD","PD","LU1829250122.USD","BK4568","LU2236285917.USD","BK4588","BK4585","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2603621919","title":"港股異動 | 維立志博-B(09887)升逾4% PD-L1/4-1BB雙抗獲FDA快速通道資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2603621919","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603621919?lang=zh_tw&edition=fundamental","pubTime":"2026-01-15 10:02","pubTimestamp":1768442529,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维立志博-B涨超4%，截至发稿，涨4.26%，报56.3港元，成交额300.03万港元。消息面上，1月14日晚，维立志博宣布，公司自主研发的抗PD-L1/4-1BB双特异性抗体维利信获得美国食品药品监督管理局授予快速通道资格认定，用于治疗肺外神经内分泌癌。这一里程碑将有力推动其全球开发进程，加速药物上市，早日惠及全球患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","HK0000252152.HKD","LU1169590202.USD","BK1161","LU1169589451.USD","BK4023","PD","HK0000500386.USD","HK0000252160.HKD"],"gpt_icon":0},{"id":"2603612075","title":"維立志博-B(09887)：維利信™(PD-L1/4-1BB雙特異性抗體奧帕替蘇米單抗，LBL-024)獲美國FDA授予快速通道資格認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2603612075","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603612075?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 22:52","pubTimestamp":1768402376,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，于2026年1月14日，PD-L1/4-1BB双特异性抗体维利信TM获美国食品药品监督管理局授予快速通道资格认定，用于治疗肺外神经内分泌癌。快速通道资格认定是FDA批准加速审查治疗严重或危及生命病情或解决未满足医疗需求的药物以助加快药物开发的方法。维利信TM是一种同时靶向PD-L1与4-1BB的双特异性抗体，为针对肺外神经内分泌癌的全球首款达到注册临床阶段的靶向4-1BB受体的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252152.HKD","PD","BK4023","HK0000252160.HKD","LU1169589451.USD","BK1161","LU1169590202.USD","09887","HK0000500386.USD"],"gpt_icon":1},{"id":"2603539575","title":"港股異動 | 復宏漢霖(02696)再升逾8% 廣譜抗腫瘤PD-L1 ADC HLX43末線食管鱗癌II期數據首次發布","url":"https://stock-news.laohu8.com/highlight/detail?id=2603539575","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603539575?lang=zh_tw&edition=fundamental","pubTime":"2026-01-13 10:12","pubTimestamp":1768270333,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖再涨超8%，截至发稿，涨8.05%，报69.8港元，成交额1864.08万港元。消息面上，1月9日，复宏汉霖在2026年美国临床肿瘤学会胃肠道肿瘤研讨会上，首度公布了其PD-L1 ADC HLX43治疗复发/转移性食管鳞癌的II期概念验证数据，本次发布的数据初步验证了HLX43在经治的晚期ESCC患者中的治疗潜力，展现出令人鼓舞的疗效及良好的安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4080","02696","ADC","HK0000165453.HKD","LU1169589451.USD","BK4231","PD","HK0000306701.USD","BK4023","LU1169590202.USD","HK0000320264.USD","HK0000320223.HKD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2603357301","title":"PD-1/VEGF雙抗交易熱潮迴歸？榮昌生物簽下56億美元授權","url":"https://stock-news.laohu8.com/highlight/detail?id=2603357301","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603357301?lang=zh_tw&edition=fundamental","pubTime":"2026-01-13 10:03","pubTimestamp":1768269780,"startTime":"0","endTime":"0","summary":"艾伯维拿下荣昌生物的双抗授权。　　1月12日晚间，中国生物医药企业荣昌生物宣布，与艾伯维达成一笔总金额高达56亿美元的授权合作。　　RC148是荣昌生物研发的一款新型靶向PD-1/VEGF的双特异性抗体药物，其设计旨在激活抗肿瘤免疫反应的同时抑制肿瘤驱动的血管生成。通过同时靶向并抑制PD-1与VEGF通路，有望通过多机制增强免疫系统的抗肿瘤活性。　　值得一提的是，康方生物PD-1/VEGF再度传来新的进展消息。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-01-13/doc-inhhcntx9294031.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-01-13/doc-inhhcntx9294031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064130708.USD","LU2328871848.SGD","BK1574","BK0239","BK1583","LU1064131003.USD","BK1161","LU2488822045.USD","LU2148510915.USD","LU1969619763.USD","LU1169589451.USD","688331","09995","PD","BK4023","LU1169590202.USD"],"gpt_icon":0},{"id":"2601562331","title":"港股異動 | 復宏漢霖(02696)盤中升逾5% 公司首次公布PD-L1 ADC食管鱗狀細胞癌Ⅱ期臨牀數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2601562331","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601562331?lang=zh_tw&edition=fundamental","pubTime":"2026-01-08 11:18","pubTimestamp":1767842338,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖盘中涨超5%，截至发稿，涨4.39%，报66.65港元，成交额2390.53万港元。其中，复宏汉霖首次公布其PD-L1 ADC药物HLX43治疗复发/转移性食管鳞状细胞癌中的临床数据。HLX43是靶向PD-L1的新型ADC药物，兼具免疫检查点抑制与细胞毒性双重作用，其I期临床已证实对免疫治疗无效患者具有前景疗效和良好耐受性。本项Ⅱ期研究旨在评估HLX43用于经治复发 / 转移性食管鳞状细胞癌患者的疗效与安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","02696","BK1161","LU1169589451.USD","BK4231","ADC","BK4023","HK0000165453.HKD","PD","BK4080"],"gpt_icon":0},{"id":"2601387879","title":"維亞臻生物VSA012注射液啓動II期臨牀 適應症為活動性狼瘡腎炎等疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2601387879","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601387879?lang=zh_tw&edition=fundamental","pubTime":"2026-01-07 18:03","pubTimestamp":1767780180,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，维亚臻生物技术（苏州）有限公司的评估VSA012注射液在中国活动性狼疮肾炎患者、原发性IgA肾病患者、C3肾小球病患者和免疫复合物介导的膜增生性肾小球肾炎患者中的有效性和安全性的多中心、开放设计的II期临床研究已启动。这些疾病均属肾脏病症，会损害肾功能，引发蛋白尿、血尿等症状，诊断依赖肾活检及相关检验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107185357a6fe6d42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107185357a6fe6d42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PD","VSA","LU1169589451.USD","BK4023","PK","BK4204","BK4218","BK4181","LU1169590202.USD"],"gpt_icon":0},{"id":"2601882903","title":"天士力：PD-L1/VEGF雙抗的實體瘤適應症IIa期、直腸癌適應症IIb期臨牀試驗正在入組中","url":"https://stock-news.laohu8.com/highlight/detail?id=2601882903","media":"证券日报 ","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601882903?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 21:36","pubTimestamp":1767620160,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n证券日报网讯 1月5日，天士力在互动平台回答投资者提问时表示，根据公司《2025年半年度报告》，PD-L1/VEGF双抗的实体瘤适应症IIa期、直肠癌适应症IIb期临床试验正在入组中；培重组人成纤维细胞生长因子21注射液，临床试验已进入Ib期。后续研发进展公司会根据信息披露相关规定进行公告。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-05/doc-inhfhpmh6572122.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-05/doc-inhfhpmh6572122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1169589451.USD","BK0188","BK0196","BK4023","PD","BK0028","BK0239","600535","BK0183","BK0012","LU1169590202.USD"],"gpt_icon":0},{"id":"2601020061","title":"科倫博泰生物-B(06990)核心產品TROP2 ADC蘆康沙妥珠單抗(SAC-TMT)聯合免疫療法帕博利珠單抗一線治療PD-L1陽性局部晚期或轉移性非小細胞肺癌獲NMPA突破性療法認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2601020061","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601020061?lang=zh_tw&edition=fundamental","pubTime":"2026-01-05 08:01","pubTimestamp":1767571299,"startTime":"0","endTime":"0","summary":"此前，公司公布了芦康沙妥珠单抗联合帕博利珠单抗一线治疗PD-L1阳性NSCLC的3期OptiTROP-Lung05临床试验结果，其在主要终点无进展生存期显示出统计学意义和临床意义的显著改善，并在总生存期方面观察到获益趋势。OptiTROP-Lung05研究是首个免疫联合ADC在一线治疗NSCLC上达到主要终点的3期临床研究。此次在一线治疗PD-L1阳性NSCLC获得突破性疗法认定，将为加速芦康沙妥珠单抗在此适应症审评与上市进程提供助力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388399.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","LU1169590202.USD","BK4231","BK1161","ADC","PD","06990","LU0196878994.USD","LU1169589451.USD","BK4023"],"gpt_icon":0},{"id":"2600089095","title":"達伯舒新適應症醫保落地 系晚期pMMR子宮內膜癌唯一醫保抗PD-(L)1藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2600089095","media":"中国网财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600089095?lang=zh_tw&edition=fundamental","pubTime":"2026-01-01 15:16","pubTimestamp":1767251765,"startTime":"0","endTime":"0","summary":"中国网财经1月1日讯今日，北京、上海、苏州、郑州等多地医院开出信迪利单抗注射液(达伯舒)新增子宫内膜癌适应症医保处方，标志着该适应症在被纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》后正式落地执行医保价格。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601013607458241.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601013607458241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1169589451.USD","BK4585","LU0210528500.USD","PD","BK4588","LU0053666078.USD","BK4023","L","BK4107","LU1169590202.USD","LU2487616109.SGD"],"gpt_icon":0},{"id":"2592795703","title":"【新股IPO】國元國際：瀚思艾泰-B(03378)CD47/PD-1雙特異性抗體具備獨特性 建議謹慎申購","url":"https://stock-news.laohu8.com/highlight/detail?id=2592795703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592795703?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 10:55","pubTimestamp":1765940103,"startTime":"0","endTime":"0","summary":"2023 年5月获FDA批准开展 HX009 Ib/II 期治疗 DLBCL 研究。公司的管线有独特的竞争优势，截至2025年12 月 1 日，全球无已获批的 CD47/PD-1 双特异性抗体产品，HX009在该靶点组合中处于唯一性地位。上市后市值在 38.14-43.59 亿港元，但考虑到公司的 CD47/PD-1 双特异性抗体有一定的独特性，如果上市之后，产品有较大的潜力，建议谨慎申购。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/NWEyNjUzNmNkZDE2ZjIxMDg2ODEwOTExNzY3Nw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NWEyNjUzNmNkZDE2ZjIxMDg2ODEwOTExNzY3Nw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971704","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1535","LU1169589451.USD","LU1169590202.USD","BK1173","PD","03378","BK4023"],"gpt_icon":1},{"id":"2591164645","title":"康辰藥業(603590.SH)：KC1036聯合PD-1抗體和含鉑化療一線治療晚期復發或轉移性食管鱗癌Ⅱ期臨牀研究完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2591164645","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591164645?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 20:05","pubTimestamp":1765800325,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康辰药业(603590.SH)发布公告，近日，公司自主研发的KC1036片(简称“KC1036”)，顺利完成“KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌临床试验(KC1036-COM-01)”首例受试者入组服药。KC1036是公司自主研发的化学药品1类创新药，公司拥有该产品的全球知识产权。KC1036通过抑制VEGFR2、AXL等多靶点实现抗肿瘤活性。KC1036具有较强的VEGFR血管靶向，抑制肿瘤细胞生长;通过抑制AXL，可以改善宿主的抗肿瘤免疫应答，从而避免肿瘤的免疫逃逸。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","LU1169589451.USD","BK4023","PD","603590","BK0239"],"gpt_icon":0},{"id":"2590504741","title":"產業新聞 | FDA授予百時美施貴寶PD-1療法組合優先審評資格；創新帕金森病免疫療法積極試驗結果公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2590504741","media":"药明康德","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590504741?lang=zh_tw&edition=fundamental","pubTime":"2025-12-12 08:00","pubTimestamp":1765497601,"startTime":"0","endTime":"0","summary":"FDA授予百时美施贵宝PD-1疗法组合优先审评资格百时美施贵宝今日宣布，美国FDA已受理Opdivo的补充生物制品许可申请，用于与多柔比星、长春花碱和达卡巴嗪联合，治疗既往未接受治疗的III期或IV期经典型霍奇金淋巴瘤成人及儿童患者。FDA授予该申请优先审评资格，并将PDUFA日期确定为2026年4月8日。此次FDA受理及优先审评的决定，主要基于3期SWOG S1826研究的积极结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212092546a443889e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212092546a443889e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU1718418525.SGD","LU2125154935.USD","BMY","LU1670711040.USD","IE00BJJMRZ35.SGD","LU1323610961.USD","LU1261432733.SGD","LU1032466523.USD","LU1093756325.SGD","IE00BFXG1179.USD","BK4023","LU0985481810.HKD","LU1571399168.USD","LU0868494617.USD","BK4534","LU0321505439.SGD","LU2133065610.SGD","LU1989771016.USD","IE00BJT1NW94.SGD","BK4585","LU0096364046.USD","LU1585245621.USD","BK4581","IE00B2B36J28.USD","LU1868836757.USD","LU0114720955.EUR","LU0882574055.USD","LU1430594728.SGD","IE00BSNM7G36.USD","IE0002141913.USD","LU2360032135.SGD","LU1169590202.USD","LU1868837136.USD","IE00BFTCPJ56.SGD","LU0321505868.SGD","IE0009355771.USD","LU1670710588.SGD","LU1868836591.USD","LU0456855351.SGD","LU2242652126.USD","LU1291159041.SGD","LU1169589451.USD","LU1670711123.USD","BK4532","BK4588","LU1868837300.USD","PD","LU2242646821.SGD","LU0267386448.USD"],"gpt_icon":0},{"id":"2590563981","title":"港股異動 | 榮昌生物(09995)盤中升逾7% 公布PD-1/VEGF雙抗非小細胞肺癌臨牀數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2590563981","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590563981?lang=zh_tw&edition=fundamental","pubTime":"2025-12-11 10:45","pubTimestamp":1765421137,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物盘中涨超7%，截至发稿，涨5.57%，报81.5港元，成交额3.1亿港元。会上，由荣昌生物自主研发的PD-1/VEGF双特异性抗体RC148单药及联合方案一线或二线治疗非小细胞肺癌的一项Ⅰ/Ⅱ期临床研究数据，以壁报形式正式发布。据悉，今年8月，RC148已获FDA批准在美国开展II期临床试验。获得FDA的IND许可，标志着该药将进入全球临床开发阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380238.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","LU2488822045.USD","LU1064131003.USD","PD","BK1574","BK4023","09995","LU1169589451.USD","688331","BK1161","LU1169590202.USD","LU2328871848.SGD","BK0239","LU2148510915.USD","BK1583","LU1064130708.USD"],"gpt_icon":0},{"id":"2589801094","title":"和譽-B(02256)：和譽醫藥於ESMO Asia 2025公布口服PD-L1抑制劑ABSK043聯合 EGFR抑制劑伏美替尼治療NSCLC的II期臨牀初步結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801094","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589801094?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 08:06","pubTimestamp":1765152368,"startTime":"0","endTime":"0","summary":"数据显示，ABSK043与伏美替尼的“靶免联合”方案展现出良好的安全性和耐受性。研究结果显示，ABSK043联合伏美替尼表现出可控的安全性和良好的耐受性。剂量递增阶段的研究结果表明，ABSK043联合伏美替尼不仅安全性可控、耐受性良好，还展现出令人鼓舞的初步抗肿瘤活性。上述积极结果为正在开展的剂量扩展阶段奠定了基础，该阶段将评估ABSK043联合伏美替尼作为一线疗法，用于治疗初治的EGFR突变、PD-L1阳性的NSCLC患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","09939","LU2778985437.USD","IE00BPRC5H50.USD","BK1574","BK1161","LU1169590202.USD","LU2488822045.USD","LU2476274720.SGD","LU1169589451.USD","PD","IE00B543WZ88.USD","159938","LU2476274308.USD","IE00B5MMRT66.SGD","02256","BK1515"],"gpt_icon":0},{"id":"2589289437","title":"ADC藥物與PD-1/VEGF雙抗聯用再添案例 科倫博泰與Crescent達成雙向授權協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2589289437","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589289437?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 19:52","pubTimestamp":1764935561,"startTime":"0","endTime":"0","summary":"12月4日，科伦博泰（HK06990）与CrescentBiopharma,Inc.（一家纳斯达克上市公司，以下简称Crescent）共同宣布，双方已建立战略合作伙伴关系。科伦博泰方面将ADC药物（抗体偶联药物）SKB105在中国以外权利授权Crescent，并预计将获得最高超13亿美元的授权收入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512053584015760.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512053584015760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PD","BK4023","LU1169590202.USD","ADC","LU1169589451.USD","BK4231","BK4080"],"gpt_icon":0},{"id":"2589865213","title":"ADC與PD-1紅海之外，寶濟藥業如何找到生物醫藥的「第二增長曲線」？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589865213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589865213?lang=zh_tw&edition=fundamental","pubTime":"2025-12-05 13:33","pubTimestamp":1764912788,"startTime":"0","endTime":"0","summary":"而在ADC、PD-1等热门靶点赛道数百家企业拥挤厮杀，从临床入组速度到未来的市场定价无不白热化的竞争中，上海宝济药业股份有限公司选择了一条截然不同的差异化战略路径。与传统疗法相比，KJ103的革命性优势则在于其“快”。目前，其领先地位和临床价值已获得监管机构的高度认可。对于KJ017而言，其市场空间并不取决于自身的销量，而是与整个千亿级生物药市场的增长深度绑定，其商业模式堪称典型的“卖水人”逻辑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161726","BK4231","ADC","BK4023","PD","399441","02659","LU1169590202.USD","LU1169589451.USD","BK4080"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":76,"code":"91000000","status":"200"}]}}